Medtronic raises profit forecast as surgeries return to pre-pandemic levels
Reuters
Published Aug 22, 2023 06:58AM ET
Updated Aug 22, 2023 12:40PM ET
By Bhanvi Satija
(Reuters) -Medtronic on Tuesday raised its annual profit forecast as the return of non-urgent surgery volumes to pre-pandemic levels boosted demand for its medical devices, sending its shares up 3%.
Medtronic (NYSE:MDT), which makes pacemakers, catheters and other tools used in heart and gastrointestinal surgeries, joins rivals, including Abbott Laboratories (NYSE:ABT), Stryker (NYSE:SYK) and Boston Scientific (NYSE:BSX), on benefiting from a rise in non-urgent surgeries.
CEO Geoff Martha said trends pointed to a recovery in surgical volumes as some procedures returned to stronger than pre-pandemic levels.
"It's been a steady flow versus like a pent-up demand. So I think that's good news for the industry," Martha said.
The Dublin-based medical device maker now expects profit to be between $5.08 per share and $5.16 per share for the fiscal year 2024, compared with the range of $5 to $5.10 per share previously expected.
Medtronic would not be doing any large or medium-scale divestitures after completing the spin off of its patient monitoring and respiratory interventions businesses, which is expected in the first half of fiscal 2025, Martha said.
The company will focus on heart or diabetes devices related tuck-in deals, which would compliment its existing portfolio, Martha added.
For the first quarter, the company's revenue of $7.70 billion came in above estimates of $7.57 billion, according to Refinitiv.
Analysts said the company's better-than-expected quarterly results were also aided by its cost-saving measures, such as job cuts, a revamp of its global supply chain and the ongoing process of offloading some smaller businesses, that offset a hit from rising raw material costs.
The internal changes at Medtronic are starting to "shine through", said Edward Jones analyst John Boylan, adding that these changes will become more apparent in subsequent quarters.
Excluding items, Medtronic reported quarterly profit of $1.20 per share that beat estimates of $1.11 per share.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.